Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 65% ± 16% | |
lung | 19 studies | 53% ± 16% | |
brain | 18 studies | 39% ± 16% | |
intestine | 13 studies | 38% ± 17% | |
kidney | 9 studies | 49% ± 17% | |
eye | 9 studies | 40% ± 15% | |
lymph node | 6 studies | 62% ± 20% | |
bone marrow | 6 studies | 48% ± 25% | |
liver | 6 studies | 48% ± 18% | |
pancreas | 5 studies | 59% ± 25% | |
uterus | 5 studies | 54% ± 17% | |
placenta | 4 studies | 60% ± 21% | |
adipose | 4 studies | 29% ± 19% | |
prostate | 4 studies | 36% ± 12% | |
breast | 4 studies | 53% ± 8% | |
heart | 3 studies | 26% ± 8% | |
adrenal gland | 3 studies | 55% ± 15% | |
esophagus | 3 studies | 52% ± 22% | |
skin | 3 studies | 36% ± 16% | |
thymus | 3 studies | 62% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 14844.67 | 21 / 21 | 100% | 201.49 | 504 / 504 |
esophagus | 100% | 15372.37 | 1445 / 1445 | 100% | 221.36 | 183 / 183 |
intestine | 100% | 14465.44 | 966 / 966 | 100% | 222.64 | 527 / 527 |
lung | 100% | 14623.87 | 578 / 578 | 100% | 156.46 | 1155 / 1155 |
ovary | 100% | 9356.24 | 180 / 180 | 100% | 156.85 | 430 / 430 |
stomach | 100% | 9825.04 | 359 / 359 | 100% | 231.68 | 286 / 286 |
uterus | 100% | 12747.65 | 170 / 170 | 100% | 168.90 | 459 / 459 |
breast | 100% | 15323.94 | 459 / 459 | 100% | 211.01 | 1117 / 1118 |
skin | 100% | 17091.59 | 1809 / 1809 | 100% | 178.79 | 471 / 472 |
brain | 100% | 20688.80 | 2636 / 2642 | 100% | 172.26 | 705 / 705 |
thymus | 100% | 13681.09 | 653 / 653 | 100% | 145.93 | 603 / 605 |
prostate | 100% | 11260.46 | 245 / 245 | 99% | 117.56 | 499 / 502 |
kidney | 100% | 13626.43 | 89 / 89 | 99% | 124.54 | 895 / 901 |
adrenal gland | 100% | 14871.92 | 258 / 258 | 98% | 122.86 | 225 / 230 |
liver | 91% | 4503.80 | 205 / 226 | 97% | 66.54 | 395 / 406 |
pancreas | 88% | 4231.39 | 288 / 328 | 99% | 146.96 | 176 / 178 |
adipose | 100% | 17335.60 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 18055.76 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 181.31 | 29 / 29 |
spleen | 100% | 16093.04 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 157.89 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 76.66 | 1 / 1 |
muscle | 99% | 7394.32 | 796 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 16771.84 | 916 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 94.08 | 77 / 80 |
heart | 96% | 8122.37 | 826 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007165 | Biological process | signal transduction |
GO_0006605 | Biological process | protein targeting |
GO_0045744 | Biological process | negative regulation of G protein-coupled receptor signaling pathway |
GO_0043085 | Biological process | positive regulation of catalytic activity |
GO_0051220 | Biological process | cytoplasmic sequestering of protein |
GO_0008104 | Biological process | protein localization |
GO_0035308 | Biological process | negative regulation of protein dephosphorylation |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0016020 | Cellular component | membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005925 | Cellular component | focal adhesion |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005774 | Cellular component | vacuolar membrane |
GO_0042470 | Cellular component | melanosome |
GO_0004860 | Molecular function | protein kinase inhibitor activity |
GO_0019899 | Molecular function | enzyme binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0045296 | Molecular function | cadherin binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0051219 | Molecular function | phosphoprotein binding |
GO_0050815 | Molecular function | phosphoserine residue binding |
GO_0005515 | Molecular function | protein binding |
GO_0042826 | Molecular function | histone deacetylase binding |
Gene name | YWHAB |
Protein name | 14-3-3 protein beta/alpha (Protein 1054) (Protein kinase C inhibitor protein 1) (KCIP-1) [Cleaved into: 14-3-3 protein beta/alpha, N-terminally processed] 14-3-3 protein beta/alpha |
Synonyms | |
Description | FUNCTION: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. . FUNCTION: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. . FUNCTION: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. . FUNCTION: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. . FUNCTION: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. . FUNCTION: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. . |
Accessions | ENST00000633979.1 ENST00000428262.1 ENST00000353703.9 [P31946-1] ENST00000445830.1 B5BU24 Q4VY20 P31946 ENST00000479421.5 A0A0J9YWZ2 Q4VY19 ENST00000372839.7 [P31946-1] A0A0J9YWE8 |